Molecular Transcriptomics-Guided Treatment Selection in a Case of Palmar Psoriasis (EADV 2026) - Aug 6, 2026 - Abstract #PCC-1090; CC-2777; Pres time: Sep 30, 2026; Location: ePoster Area; "Oral alitretinoin did not lead to relevant improvement. Oral ciclosporin resulted in a partial regression of the skin lesions, but no sustained complete remission. Additionally, topical delgocitinib cream as an add-on therapy also failed to achieve full symptom control...Based on this molecular profile, treatment with the IL-17A/F inhibitor bimekizumab was initiated subcutaneously...In this case, NanoString-based molecular profiling identified a Th17-dominant signature in a patient with diagnostically challenging chronic palmar inflammatory dermatosis and successfully guided treatment selection with IL-17A/F inhibition. This case supports the potential value of transcriptomic profiling as a practical decision-support tool in difficult to treat palmoplantar inflammatory dermatoses cases."
Clinical • Conjunctivitis • Contact Dermatitis • Dermatology • Immunology • Infectious Disease • Ocular Infections • Ocular Inflammation • Ophthalmology • Psoriasis • IL17A
|
|
Alexandra Junge; Nikhil Yawalkar; Simone Cazzaniga; Antoine Girardin; Jeremy Di Domizio; Michel Gilliet; Christoph Schlapbach
|